According to China's clinical trials of COVID-19 treatment, the number of chemical drugs accounted for the highest proportion, followed by biological drugs, cell therapy, vaccines, and traditional Chinese medicine. Among the biological drugs, IL-6 related monoclonal antibodies (anti-inflammatory) account for the largest proportion, including tocilizumab and Sarilumab. This report focuses on the investigation and analysis of biologic medication and predicts the future market development of biopharmaceuticals under the influence of COVID-19. Biological drugs are mainly divided into two categories: neutralizing antibodies and anti-inflammatory drugs. The main subdivisions include: IL-6, C5a, CD147, PD-1 and Interferon (beta-1a), etc.
Market Analysis and Insights: Global Biologic Medication in COVID-19 Market
The global Biologic Medication in COVID-19 market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Biologic Medication in COVID-19 market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Biologic Medication in COVID-19 market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Biologic Medication in COVID-19 market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Biologic Medication in COVID-19 market.
Global Biologic Medication in COVID-19 Scope and Market Size
Biologic Medication in COVID-19 market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Biologic Medication in COVID-19 market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Neutralizing Antibodies
Anti-inflammatory Drugs
Segment by Application
COVID-19
Influenza
Malaria
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Roche
Sanofi
Novartis
Merck
Bayer
Shutaishen
Biogen
Regeneron Pharmaceuticals
Vir Biotech
Junshi Biosciences
Anke Biotechnology
OncoImmune
Market Analysis and Insights: Global Biologic Medication in COVID-19 Market
The global Biologic Medication in COVID-19 market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Biologic Medication in COVID-19 market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Biologic Medication in COVID-19 market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Biologic Medication in COVID-19 market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Biologic Medication in COVID-19 market.
Global Biologic Medication in COVID-19 Scope and Market Size
Biologic Medication in COVID-19 market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Biologic Medication in COVID-19 market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Neutralizing Antibodies
Anti-inflammatory Drugs
Segment by Application
COVID-19
Influenza
Malaria
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Roche
Sanofi
Novartis
Merck
Bayer
Shutaishen
Biogen
Regeneron Pharmaceuticals
Vir Biotech
Junshi Biosciences
Anke Biotechnology
OncoImmune
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Biologic Medication in COVID-19 Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Neutralizing Antibodies
1.2.3 Anti-inflammatory Drugs
1.3 Market by Application
1.3.1 Global Biologic Medication in COVID-19 Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 COVID-19
1.3.3 Influenza
1.3.4 Malaria
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Biologic Medication in COVID-19 Market Perspective (2016-2027)
2.2 Biologic Medication in COVID-19 Growth Trends by Regions
2.2.1 Biologic Medication in COVID-19 Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Biologic Medication in COVID-19 Historic Market Share by Regions (2016-2021)
2.2.3 Biologic Medication in COVID-19 Forecasted Market Size by Regions (2022-2027)
2.3 Biologic Medication in COVID-19 Industry Dynamic
2.3.1 Biologic Medication in COVID-19 Market Trends
2.3.2 Biologic Medication in COVID-19 Market Drivers
2.3.3 Biologic Medication in COVID-19 Market Challenges
2.3.4 Biologic Medication in COVID-19 Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Biologic Medication in COVID-19 Players by Revenue
3.1.1 Global Top Biologic Medication in COVID-19 Players by Revenue (2016-2021)
3.1.2 Global Biologic Medication in COVID-19 Revenue Market Share by Players (2016-2021)
3.2 Global Biologic Medication in COVID-19 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Biologic Medication in COVID-19 Revenue
3.4 Global Biologic Medication in COVID-19 Market Concentration Ratio
3.4.1 Global Biologic Medication in COVID-19 Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Biologic Medication in COVID-19 Revenue in 2020
3.5 Biologic Medication in COVID-19 Key Players Head office and Area Served
3.6 Key Players Biologic Medication in COVID-19 Product Solution and Service
3.7 Date of Enter into Biologic Medication in COVID-19 Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Biologic Medication in COVID-19 Breakdown Data by Type
4.1 Global Biologic Medication in COVID-19 Historic Market Size by Type (2016-2021)
4.2 Global Biologic Medication in COVID-19 Forecasted Market Size by Type (2022-2027)
5 Biologic Medication in COVID-19 Breakdown Data by Application
5.1 Global Biologic Medication in COVID-19 Historic Market Size by Application (2016-2021)
5.2 Global Biologic Medication in COVID-19 Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Biologic Medication in COVID-19 Market Size (2016-2027)
6.2 North America Biologic Medication in COVID-19 Market Size by Type
6.2.1 North America Biologic Medication in COVID-19 Market Size by Type (2016-2021)
6.2.2 North America Biologic Medication in COVID-19 Market Size by Type (2022-2027)
6.2.3 North America Biologic Medication in COVID-19 Market Size by Type (2016-2027)
6.3 North America Biologic Medication in COVID-19 Market Size by Application
6.3.1 North America Biologic Medication in COVID-19 Market Size by Application (2016-2021)
6.3.2 North America Biologic Medication in COVID-19 Market Size by Application (2022-2027)
6.3.3 North America Biologic Medication in COVID-19 Market Size by Application (2016-2027)
6.4 North America Biologic Medication in COVID-19 Market Size by Country
6.4.1 North America Biologic Medication in COVID-19 Market Size by Country (2016-2021)
6.4.2 North America Biologic Medication in COVID-19 Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Biologic Medication in COVID-19 Market Size (2016-2027)
7.2 Europe Biologic Medication in COVID-19 Market Size by Type
7.2.1 Europe Biologic Medication in COVID-19 Market Size by Type (2016-2021)
7.2.2 Europe Biologic Medication in COVID-19 Market Size by Type (2022-2027)
7.2.3 Europe Biologic Medication in COVID-19 Market Size by Type (2016-2027)
7.3 Europe Biologic Medication in COVID-19 Market Size by Application
7.3.1 Europe Biologic Medication in COVID-19 Market Size by Application (2016-2021)
7.3.2 Europe Biologic Medication in COVID-19 Market Size by Application (2022-2027)
7.3.3 Europe Biologic Medication in COVID-19 Market Size by Application (2016-2027)
7.4 Europe Biologic Medication in COVID-19 Market Size by Country
7.4.1 Europe Biologic Medication in COVID-19 Market Size by Country (2016-2021)
7.4.2 Europe Biologic Medication in COVID-19 Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Biologic Medication in COVID-19 Market Size (2016-2027)
8.2 Asia-Pacific Biologic Medication in COVID-19 Market Size by Type
8.2.1 Asia-Pacific Biologic Medication in COVID-19 Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Biologic Medication in COVID-19 Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Biologic Medication in COVID-19 Market Size by Type (2016-2027)
8.3 Asia-Pacific Biologic Medication in COVID-19 Market Size by Application
8.3.1 Asia-Pacific Biologic Medication in COVID-19 Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Biologic Medication in COVID-19 Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Biologic Medication in COVID-19 Market Size by Application (2016-2027)
8.4 Asia-Pacific Biologic Medication in COVID-19 Market Size by Region
8.4.1 Asia-Pacific Biologic Medication in COVID-19 Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Biologic Medication in COVID-19 Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Biologic Medication in COVID-19 Market Size (2016-2027)
9.2 Latin America Biologic Medication in COVID-19 Market Size by Type
9.2.1 Latin America Biologic Medication in COVID-19 Market Size by Type (2016-2021)
9.2.2 Latin America Biologic Medication in COVID-19 Market Size by Type (2022-2027)
9.2.3 Latin America Biologic Medication in COVID-19 Market Size by Type (2016-2027)
9.3 Latin America Biologic Medication in COVID-19 Market Size by Application
9.3.1 Latin America Biologic Medication in COVID-19 Market Size by Application (2016-2021)
9.3.2 Latin America Biologic Medication in COVID-19 Market Size by Application (2022-2027)
9.3.3 Latin America Biologic Medication in COVID-19 Market Size by Application (2016-2027)
9.4 Latin America Biologic Medication in COVID-19 Market Size by Country
9.4.1 Latin America Biologic Medication in COVID-19 Market Size by Country (2016-2021)
9.4.2 Latin America Biologic Medication in COVID-19 Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Biologic Medication in COVID-19 Market Size (2016-2027)
10.2 Middle East & Africa Biologic Medication in COVID-19 Market Size by Type
10.2.1 Middle East & Africa Biologic Medication in COVID-19 Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Biologic Medication in COVID-19 Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Biologic Medication in COVID-19 Market Size by Type (2016-2027)
10.3 Middle East & Africa Biologic Medication in COVID-19 Market Size by Application
10.3.1 Middle East & Africa Biologic Medication in COVID-19 Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Biologic Medication in COVID-19 Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Biologic Medication in COVID-19 Market Size by Application (2016-2027)
10.4 Middle East & Africa Biologic Medication in COVID-19 Market Size by Country
10.4.1 Middle East & Africa Biologic Medication in COVID-19 Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Biologic Medication in COVID-19 Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Biologic Medication in COVID-19 Introduction
11.1.4 Roche Revenue in Biologic Medication in COVID-19 Business (2016-2021)
11.1.5 Roche Recent Development
11.2 Sanofi
11.2.1 Sanofi Company Details
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Biologic Medication in COVID-19 Introduction
11.2.4 Sanofi Revenue in Biologic Medication in COVID-19 Business (2016-2021)
11.2.5 Sanofi Recent Development
11.3 Novartis
11.3.1 Novartis Company Details
11.3.2 Novartis Business Overview
11.3.3 Novartis Biologic Medication in COVID-19 Introduction
11.3.4 Novartis Revenue in Biologic Medication in COVID-19 Business (2016-2021)
11.3.5 Novartis Recent Development
11.4 Merck
11.4.1 Merck Company Details
11.4.2 Merck Business Overview
11.4.3 Merck Biologic Medication in COVID-19 Introduction
11.4.4 Merck Revenue in Biologic Medication in COVID-19 Business (2016-2021)
11.4.5 Merck Recent Development
11.5 Bayer
11.5.1 Bayer Company Details
11.5.2 Bayer Business Overview
11.5.3 Bayer Biologic Medication in COVID-19 Introduction
11.5.4 Bayer Revenue in Biologic Medication in COVID-19 Business (2016-2021)
11.5.5 Bayer Recent Development
11.6 Shutaishen
11.6.1 Shutaishen Company Details
11.6.2 Shutaishen Business Overview
11.6.3 Shutaishen Biologic Medication in COVID-19 Introduction
11.6.4 Shutaishen Revenue in Biologic Medication in COVID-19 Business (2016-2021)
11.6.5 Shutaishen Recent Development
11.7 Biogen
11.7.1 Biogen Company Details
11.7.2 Biogen Business Overview
11.7.3 Biogen Biologic Medication in COVID-19 Introduction
11.7.4 Biogen Revenue in Biologic Medication in COVID-19 Business (2016-2021)
11.7.5 Biogen Recent Development
11.8 Regeneron Pharmaceuticals
11.8.1 Regeneron Pharmaceuticals Company Details
11.8.2 Regeneron Pharmaceuticals Business Overview
11.8.3 Regeneron Pharmaceuticals Biologic Medication in COVID-19 Introduction
11.8.4 Regeneron Pharmaceuticals Revenue in Biologic Medication in COVID-19 Business (2016-2021)
11.8.5 Regeneron Pharmaceuticals Recent Development
11.9 Vir Biotech
11.9.1 Vir Biotech Company Details
11.9.2 Vir Biotech Business Overview
11.9.3 Vir Biotech Biologic Medication in COVID-19 Introduction
11.9.4 Vir Biotech Revenue in Biologic Medication in COVID-19 Business (2016-2021)
11.9.5 Vir Biotech Recent Development
11.10 Junshi Biosciences
11.10.1 Junshi Biosciences Company Details
11.10.2 Junshi Biosciences Business Overview
11.10.3 Junshi Biosciences Biologic Medication in COVID-19 Introduction
11.10.4 Junshi Biosciences Revenue in Biologic Medication in COVID-19 Business (2016-2021)
11.10.5 Junshi Biosciences Recent Development
11.11 Anke Biotechnology
11.11.1 Anke Biotechnology Company Details
11.11.2 Anke Biotechnology Business Overview
11.11.3 Anke Biotechnology Biologic Medication in COVID-19 Introduction
11.11.4 Anke Biotechnology Revenue in Biologic Medication in COVID-19 Business (2016-2021)
11.11.5 Anke Biotechnology Recent Development
11.12 OncoImmune
11.12.1 OncoImmune Company Details
11.12.2 OncoImmune Business Overview
11.12.3 OncoImmune Biologic Medication in COVID-19 Introduction
11.12.4 OncoImmune Revenue in Biologic Medication in COVID-19 Business (2016-2021)
11.12.5 OncoImmune Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Biologic Medication in COVID-19 Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Neutralizing Antibodies
1.2.3 Anti-inflammatory Drugs
1.3 Market by Application
1.3.1 Global Biologic Medication in COVID-19 Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 COVID-19
1.3.3 Influenza
1.3.4 Malaria
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Biologic Medication in COVID-19 Market Perspective (2016-2027)
2.2 Biologic Medication in COVID-19 Growth Trends by Regions
2.2.1 Biologic Medication in COVID-19 Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Biologic Medication in COVID-19 Historic Market Share by Regions (2016-2021)
2.2.3 Biologic Medication in COVID-19 Forecasted Market Size by Regions (2022-2027)
2.3 Biologic Medication in COVID-19 Industry Dynamic
2.3.1 Biologic Medication in COVID-19 Market Trends
2.3.2 Biologic Medication in COVID-19 Market Drivers
2.3.3 Biologic Medication in COVID-19 Market Challenges
2.3.4 Biologic Medication in COVID-19 Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Biologic Medication in COVID-19 Players by Revenue
3.1.1 Global Top Biologic Medication in COVID-19 Players by Revenue (2016-2021)
3.1.2 Global Biologic Medication in COVID-19 Revenue Market Share by Players (2016-2021)
3.2 Global Biologic Medication in COVID-19 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Biologic Medication in COVID-19 Revenue
3.4 Global Biologic Medication in COVID-19 Market Concentration Ratio
3.4.1 Global Biologic Medication in COVID-19 Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Biologic Medication in COVID-19 Revenue in 2020
3.5 Biologic Medication in COVID-19 Key Players Head office and Area Served
3.6 Key Players Biologic Medication in COVID-19 Product Solution and Service
3.7 Date of Enter into Biologic Medication in COVID-19 Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Biologic Medication in COVID-19 Breakdown Data by Type
4.1 Global Biologic Medication in COVID-19 Historic Market Size by Type (2016-2021)
4.2 Global Biologic Medication in COVID-19 Forecasted Market Size by Type (2022-2027)
5 Biologic Medication in COVID-19 Breakdown Data by Application
5.1 Global Biologic Medication in COVID-19 Historic Market Size by Application (2016-2021)
5.2 Global Biologic Medication in COVID-19 Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Biologic Medication in COVID-19 Market Size (2016-2027)
6.2 North America Biologic Medication in COVID-19 Market Size by Type
6.2.1 North America Biologic Medication in COVID-19 Market Size by Type (2016-2021)
6.2.2 North America Biologic Medication in COVID-19 Market Size by Type (2022-2027)
6.2.3 North America Biologic Medication in COVID-19 Market Size by Type (2016-2027)
6.3 North America Biologic Medication in COVID-19 Market Size by Application
6.3.1 North America Biologic Medication in COVID-19 Market Size by Application (2016-2021)
6.3.2 North America Biologic Medication in COVID-19 Market Size by Application (2022-2027)
6.3.3 North America Biologic Medication in COVID-19 Market Size by Application (2016-2027)
6.4 North America Biologic Medication in COVID-19 Market Size by Country
6.4.1 North America Biologic Medication in COVID-19 Market Size by Country (2016-2021)
6.4.2 North America Biologic Medication in COVID-19 Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Biologic Medication in COVID-19 Market Size (2016-2027)
7.2 Europe Biologic Medication in COVID-19 Market Size by Type
7.2.1 Europe Biologic Medication in COVID-19 Market Size by Type (2016-2021)
7.2.2 Europe Biologic Medication in COVID-19 Market Size by Type (2022-2027)
7.2.3 Europe Biologic Medication in COVID-19 Market Size by Type (2016-2027)
7.3 Europe Biologic Medication in COVID-19 Market Size by Application
7.3.1 Europe Biologic Medication in COVID-19 Market Size by Application (2016-2021)
7.3.2 Europe Biologic Medication in COVID-19 Market Size by Application (2022-2027)
7.3.3 Europe Biologic Medication in COVID-19 Market Size by Application (2016-2027)
7.4 Europe Biologic Medication in COVID-19 Market Size by Country
7.4.1 Europe Biologic Medication in COVID-19 Market Size by Country (2016-2021)
7.4.2 Europe Biologic Medication in COVID-19 Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Biologic Medication in COVID-19 Market Size (2016-2027)
8.2 Asia-Pacific Biologic Medication in COVID-19 Market Size by Type
8.2.1 Asia-Pacific Biologic Medication in COVID-19 Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Biologic Medication in COVID-19 Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Biologic Medication in COVID-19 Market Size by Type (2016-2027)
8.3 Asia-Pacific Biologic Medication in COVID-19 Market Size by Application
8.3.1 Asia-Pacific Biologic Medication in COVID-19 Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Biologic Medication in COVID-19 Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Biologic Medication in COVID-19 Market Size by Application (2016-2027)
8.4 Asia-Pacific Biologic Medication in COVID-19 Market Size by Region
8.4.1 Asia-Pacific Biologic Medication in COVID-19 Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Biologic Medication in COVID-19 Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Biologic Medication in COVID-19 Market Size (2016-2027)
9.2 Latin America Biologic Medication in COVID-19 Market Size by Type
9.2.1 Latin America Biologic Medication in COVID-19 Market Size by Type (2016-2021)
9.2.2 Latin America Biologic Medication in COVID-19 Market Size by Type (2022-2027)
9.2.3 Latin America Biologic Medication in COVID-19 Market Size by Type (2016-2027)
9.3 Latin America Biologic Medication in COVID-19 Market Size by Application
9.3.1 Latin America Biologic Medication in COVID-19 Market Size by Application (2016-2021)
9.3.2 Latin America Biologic Medication in COVID-19 Market Size by Application (2022-2027)
9.3.3 Latin America Biologic Medication in COVID-19 Market Size by Application (2016-2027)
9.4 Latin America Biologic Medication in COVID-19 Market Size by Country
9.4.1 Latin America Biologic Medication in COVID-19 Market Size by Country (2016-2021)
9.4.2 Latin America Biologic Medication in COVID-19 Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Biologic Medication in COVID-19 Market Size (2016-2027)
10.2 Middle East & Africa Biologic Medication in COVID-19 Market Size by Type
10.2.1 Middle East & Africa Biologic Medication in COVID-19 Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Biologic Medication in COVID-19 Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Biologic Medication in COVID-19 Market Size by Type (2016-2027)
10.3 Middle East & Africa Biologic Medication in COVID-19 Market Size by Application
10.3.1 Middle East & Africa Biologic Medication in COVID-19 Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Biologic Medication in COVID-19 Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Biologic Medication in COVID-19 Market Size by Application (2016-2027)
10.4 Middle East & Africa Biologic Medication in COVID-19 Market Size by Country
10.4.1 Middle East & Africa Biologic Medication in COVID-19 Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Biologic Medication in COVID-19 Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Biologic Medication in COVID-19 Introduction
11.1.4 Roche Revenue in Biologic Medication in COVID-19 Business (2016-2021)
11.1.5 Roche Recent Development
11.2 Sanofi
11.2.1 Sanofi Company Details
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Biologic Medication in COVID-19 Introduction
11.2.4 Sanofi Revenue in Biologic Medication in COVID-19 Business (2016-2021)
11.2.5 Sanofi Recent Development
11.3 Novartis
11.3.1 Novartis Company Details
11.3.2 Novartis Business Overview
11.3.3 Novartis Biologic Medication in COVID-19 Introduction
11.3.4 Novartis Revenue in Biologic Medication in COVID-19 Business (2016-2021)
11.3.5 Novartis Recent Development
11.4 Merck
11.4.1 Merck Company Details
11.4.2 Merck Business Overview
11.4.3 Merck Biologic Medication in COVID-19 Introduction
11.4.4 Merck Revenue in Biologic Medication in COVID-19 Business (2016-2021)
11.4.5 Merck Recent Development
11.5 Bayer
11.5.1 Bayer Company Details
11.5.2 Bayer Business Overview
11.5.3 Bayer Biologic Medication in COVID-19 Introduction
11.5.4 Bayer Revenue in Biologic Medication in COVID-19 Business (2016-2021)
11.5.5 Bayer Recent Development
11.6 Shutaishen
11.6.1 Shutaishen Company Details
11.6.2 Shutaishen Business Overview
11.6.3 Shutaishen Biologic Medication in COVID-19 Introduction
11.6.4 Shutaishen Revenue in Biologic Medication in COVID-19 Business (2016-2021)
11.6.5 Shutaishen Recent Development
11.7 Biogen
11.7.1 Biogen Company Details
11.7.2 Biogen Business Overview
11.7.3 Biogen Biologic Medication in COVID-19 Introduction
11.7.4 Biogen Revenue in Biologic Medication in COVID-19 Business (2016-2021)
11.7.5 Biogen Recent Development
11.8 Regeneron Pharmaceuticals
11.8.1 Regeneron Pharmaceuticals Company Details
11.8.2 Regeneron Pharmaceuticals Business Overview
11.8.3 Regeneron Pharmaceuticals Biologic Medication in COVID-19 Introduction
11.8.4 Regeneron Pharmaceuticals Revenue in Biologic Medication in COVID-19 Business (2016-2021)
11.8.5 Regeneron Pharmaceuticals Recent Development
11.9 Vir Biotech
11.9.1 Vir Biotech Company Details
11.9.2 Vir Biotech Business Overview
11.9.3 Vir Biotech Biologic Medication in COVID-19 Introduction
11.9.4 Vir Biotech Revenue in Biologic Medication in COVID-19 Business (2016-2021)
11.9.5 Vir Biotech Recent Development
11.10 Junshi Biosciences
11.10.1 Junshi Biosciences Company Details
11.10.2 Junshi Biosciences Business Overview
11.10.3 Junshi Biosciences Biologic Medication in COVID-19 Introduction
11.10.4 Junshi Biosciences Revenue in Biologic Medication in COVID-19 Business (2016-2021)
11.10.5 Junshi Biosciences Recent Development
11.11 Anke Biotechnology
11.11.1 Anke Biotechnology Company Details
11.11.2 Anke Biotechnology Business Overview
11.11.3 Anke Biotechnology Biologic Medication in COVID-19 Introduction
11.11.4 Anke Biotechnology Revenue in Biologic Medication in COVID-19 Business (2016-2021)
11.11.5 Anke Biotechnology Recent Development
11.12 OncoImmune
11.12.1 OncoImmune Company Details
11.12.2 OncoImmune Business Overview
11.12.3 OncoImmune Biologic Medication in COVID-19 Introduction
11.12.4 OncoImmune Revenue in Biologic Medication in COVID-19 Business (2016-2021)
11.12.5 OncoImmune Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Research Methodology
SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.
PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.
MARKET ENGINEERING
The market engineering phase involves analysing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.
EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.
REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.